Search Results

VarmX to Attend LSX World Congress and Bio€quity Europe in Q2 2024

VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, announces that it will be attending the LSX World Congress and presenting at Bio€quity Europe.

March 28, 2024

·

1 min read

Business

VarmX Promotes CSO Dr. Jeffrey Lawson to New CEO and Moves to New State-of-the-Art Facility

VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, announces that Dr. Jeffrey Lawson, currently the Company’s Chief Scientific Officer, will assume the role of CEO, succeeding Dr. Jan Öhrström who will continue as Chairman.

October 12, 2023

·

3 min read

VarmX Raises €30 Million Series B2 Financing for IND Approval and Preparations for Pivotal Trial

VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces it has successfully raised an additional €30 million in a Series B2 financing round.

May 25, 2023

·

5 min read

Business

VarmX Appoints Dr. Jeffrey Lawson, MD, PhD as Chief Scientific Officer

VarmX today announces the appointment of Dr. Jeffrey Lawson as its new Chief Scientific Officer (CSO).

March 8, 2023

·

4 min read

First Subjects Dosed in First-in-Human Trial for VarmX’s Anticoagulant Reversal Agent, VMX-C001

VarmX announced treatment of the first subjects in its first-in-human study for lead compound VMX-C001, and the transition of VarmX from a preclinical into a clinical company.

December 15, 2021

·

3 min read

VarmX Awarded Funding From the EIC Accelerator to Support Scale up and Manufacturing of VMX-C001

VarmX has been awarded up to €17.5 million from the European Innovation Council Accelerator, subject to negotiation, to upscale and accelerate cost effective manufacturing of its lead compound, VMX-C001.

October 21, 2021

·

3 min read

Business

VarmX appoints Dr. Gerard Short as Chief Medical Officer

VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, announces the appointment of Dr. Gerard Short, MBBS, as Chief Medical Officer.

January 27, 2021

·

3 min read

Deals

VarmX Raises €32 Million in Series B Financing to Develop Innovative Reversal Agent for the Treatment and Prevention of Severe Bleeding in Patients on Oral Anticoagulants

VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, announces the completion of a €32 million Series B financing round.

July 8, 2020

·

8 min read

VarmX Raises € 12.5 Million to Develop Modified Blood Coagulation Factor X for Treating Severe Bleeding in Patients Using Anti-Coagulants

VarmX, today announced the closing of a Series A financing round of € 7.5 million.

July 2, 2018

·

7 min read

VarmX Raises Seed Capital For Development Of Modified Blood Coagulation Factor X

June 27, 2017

·

4 min read